LNP | Jotup

Vernal Biosciences Announces Strategic Leadership Appointments to Drive Growth in mRNA and LNP Formulation

Retrieved on:

Wednesday, January 3, 2024

Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, and Richard P. Hamel, Chief Financial Officer to its leadership team.

Key Points:

Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, and Richard P. Hamel, Chief Financial Officer to its leadership team.
His team will help customers define their manufacturing needs and provide creative solutions that leverage Vernal’s innovative technologies and manufacturing operations.
Prior to joining Vernal, Sven was a Board Member and the Chief Commercial Officer at BioCina, an Australian based CDMO.
Their additions to our team will help Vernal democratize access to high purity mRNA and LNPs for all stages of research and development.”

ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia

Retrieved on:

Wednesday, January 3, 2024

“This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.

Key Points:

“This is the first time a patient with PCD has received a targeted mRNA-based therapeutic,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer of ReCode Therapeutics.
“This study will evaluate RCT1100 as a potential novel treatment option for patients who do not have any approved therapies.
The DNAI1 mRNA is intended to establish or restore proper ciliary function by addressing the underlying cause of the disease.
This study brings us one step closer to improving the respiratory health and quality of life of people living with this disease.”

Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma

Retrieved on:

Monday, December 18, 2023

LNP, RNA, Biotechnology, Messenger, Lung, Snap, Vaccine, Respiratory failure, Trial of the century, Inhalation, Pharmacokinetics, Asthma, SARS-CoV-2, Patient, Safety, Therapy

ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform.

Key Points:

ETH47 was also designed to be administered locally to the lung through inhalation or nasal spray using the company’s proprietary Stabilized NanoParticle (SNaP) LNP platform.
The Phase 1 study will primarily evaluate ETH47’s safety and tolerability in healthy participants.
The program, although initially focused on virus-induced asthma, has the potential to be applied for pandemic preparedness against influenza and SARS-CoV-2 due to its broad applicability.
The study will contain 3 parts based on the type of delivery of ETH47, which includes nasal, inhaled and a nasal/inhaled combination.

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Retrieved on:

Thursday, December 7, 2023

LNP, RNA, Liver, ADAR, Pizzicato, Disease, SNV, Mouse, Doctor of Philosophy, Human, A1AT, Mutation, AATD, Patient, Piz, Vaccine

KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant.

Key Points:

KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant.
Preclinical development of KRRO-110 is ongoing in preparation for a potential regulatory filing in the second half of 2024.
“Selecting a development candidate for our AATD program is an important milestone for Korro, but more importantly, for patients.
“Korro’s RNA editing approach has the potential to be transformative for AATD patients and Korro is well-positioned to deliver a best-in-class therapeutic.

20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program

Retrieved on:

Wednesday, November 29, 2023

Commercialization, LNP, Sanofi, London Business School, Drug discovery, Messenger, Nuclear power plant, CEPI, JPMorgan Chase, Therapy, Duke University, University, Market access, TouchLight, Regulatory affairs, PNP, Publication, Infection, Vaccine

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.

Key Points:

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.
Hugo Fry has 29 years of leadership experience in the pharmaceutical and biotechnology industry across multiple business models, therapeutic areas, and companies, including Sanofi.
Hugo has a strong and recent track record of business development and licensing deals in the pharma and biotech sectors.
+++ Meet the 20Med Therapeutics team in San Francisco during the JPMorgan week, January 8-12, 2024 to discuss partnering opportunities around our PNP mRNA vaccine delivery platform +++

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Retrieved on:

Tuesday, November 28, 2023

RNA, LNP, Biotechnology, Harvard University, Doctor of Philosophy, Brandeis University, Alnylam Pharmaceuticals, Third Rock Ventures, Senior, Management

CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform, today announced the appointment of Rachel Meyers, PhD, to the Company’s Board of Directors.

Key Points:

CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform, today announced the appointment of Rachel Meyers, PhD, to the Company’s Board of Directors.
“Rachel is one of the pioneers in advancing LNP and conjugate-based oligonucleotide therapies to the clinic and generating regulatory approvals,” said Ram Aiyar, PhD, Chief Executive Officer of Korro.
Dr. Meyers is a seasoned biotechnology veteran whose experience in life sciences spans over two decades.
Joining the Board of Directors of Korro, a company leading the way in advancing this field, is very exciting,” said Dr. Meyers.

EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Retrieved on:

Tuesday, December 26, 2023

ET / 3 p.m. CET

Key Points:

ET / 3 p.m. CET
TÜBINGEN, Germany/BOSTON, USA – November 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2023 and provided a business update.
Positive preliminary data reported in early 2023 in COVID-19 and flu provided strong validation of CureVac’s mRNA technology platform.
All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
The first nine months of 2022 were positively impacted by €36.8 million related to the reversal of an outstanding CRO provision.

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

Retrieved on:

Friday, November 17, 2023

License, Therapy, Research, LNP, POZ, Contributor License Agreement, RNA, Pharmaceutical industry, Pfizer

HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.

Key Points:

HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.
“We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities,” stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics.
“The license agreement represents an important milestone for Serina.”

Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure

Retrieved on:

Monday, November 13, 2023

Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.

Key Points:

Under the terms of the agreement, Heqet Therapeutics will lead the development of the program, while Ethris will provide its proprietary Stabilized NanoParticle (SNaP) LNP platform to deliver ncRNA payloads to the heart tissue.
"Our RNA delivery platform was designed to deliver any type of RNA payload to a broad range of tissues," said Dr. Carsten Rudolph, CEO of Ethris.
Under the terms of the collaboration agreement, Ethris and Heqet will operate under a comprehensive commercial agreement, which encompasses various milestone and royalty payments.
By harnessing Ethris' SNaP LNP platform for precise delivery, Heqet aims to test the efficacy of its ncRNA candidates to stimulate cardiac regeneration in patients with myocardial infarction and heart failure.

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

Retrieved on:

Thursday, November 9, 2023

Cytokine, DNA, Spleen, D, Haemophilia, Gene, Therapeutic index, Liver, Tissue, Mouse, Cell, Research, ESGCT, G&A, Messenger, LNP, Innate lymphoid cell, NHP, Moderna, R, Congress, RNA, Vaccine

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results.

Key Points:

(Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results.
“The recent advances in our immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms represent two breakthroughs in the field of genetic medicine,” said Geoff McDonough, chief executive officer of Generation Bio.
R&D Expenses: Research and development (R&D) expenses were $21.9 million for the quarter ended September 30, 2023, compared to $21.2 million for the quarter ended September 30, 2022.
G&A Expenses: General and administrative (G&A) expenses were $11.6 million for the quarter ended September 30, 2023, compared to $11.5 million for the quarter ended September 30, 2022.